EVI-1 Oncogene Expression Predicts Survival in Chronic-Phase CML Patients Resistant to Imatinib Treated With Second-Generation Tyrosine Kinase Inhibitors
Blood - United States
doi 10.1182/blood-2010-01-264234
Full Text
Open PDFAbstract
Available in full text
Date
December 23, 2010
Authors
Publisher
American Society of Hematology